atenolol and pravastatin

atenolol has been researched along with pravastatin in 21 studies

Research

Studies (21)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (9.52)18.2507
2000's11 (52.38)29.6817
2010's8 (38.10)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL1
Lombardo, F; Obach, RS; Waters, NJ1
Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM1
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV1
Chen, L; He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Wang, Y; Zhang, W1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
Campillo, NE; Guerra, A; Páez, JA1
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV1
Bellera, CL; Bruno-Blanch, LE; Castro, EA; Duchowicz, PR; Goodarzi, M; Ortiz, EV; Pesce, G; Talevi, A1
Annand, R; Gozalbes, R; Jacewicz, M; Pineda-Lucena, A; Tsaioun, K1
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Arsenescu, I; Provendier, O; Witchitz, S1
Foss, OP; Graff-Iversen, S; Graving, B; Istad, H; Søyland, E; Tjeldflaat, L1
Chisholm, DJ; Greenfield, JR1
Liebson, PR1
Achimastos, A; Bairaktari, E; Elisaf, M; Ganotakis, E; Hasiotis, G; Kostoula, A; Mikhailidis, DP; Rizos, E1
Diener, HC1
Fomin, VV; Moiseev, SV1
Kumar, V; Shah, RP; Singh, S1
Alexander, MR; Burley, JC; Khaled, SA; Roberts, CJ; Yang, J1

Reviews

2 review(s) available for atenolol and pravastatin

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016
[Hypertension combined with atherosclerotic lesions in carotid arteries: should angiotensin converting enzyme inhibitors be prescribed?].
    Kardiologiia, 2005, Volume: 45, Issue:12

    Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anticholesteremic Agents; Antihypertensive Agents; Atenolol; Calcium Channel Blockers; Carotid Artery Diseases; Carotid Artery, Common; Chlorthalidone; Drug Therapy, Combination; Female; Fosinopril; Humans; Hypertension; Male; Middle Aged; Pravastatin; Randomized Controlled Trials as Topic; Risk Factors; Time Factors; Ultrasonography; Vasodilator Agents; Verapamil

2005

Trials

4 trial(s) available for atenolol and pravastatin

ArticleYear
[Comparative effects of captopril and atenolol on lipid metabolism in hypertensive hypercholesterolemic patients treated with pravastatin. A multicenter controlled trial].
    Presse medicale (Paris, France : 1983), 1996, Dec-21, Volume: 25, Issue:40

    Topics: Adult; Aged; Anticholesteremic Agents; Antihypertensive Agents; Atenolol; Captopril; Double-Blind Method; Female; Humans; Hypercholesterolemia; Hypertension; Lipid Metabolism; Male; Middle Aged; Pravastatin; Time Factors

1996
Treatment of hypertensive and hypercholesterolaemic patients in general practice. The effect of captopril, atenolol and pravastatin combined with life style intervention.
    Scandinavian journal of primary health care, 1999, Volume: 17, Issue:2

    Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anticholesteremic Agents; Atenolol; Captopril; Combined Modality Therapy; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypercholesterolemia; Hypertension; Life Style; Male; Middle Aged; Norway; Pravastatin; Statistics, Nonparametric

1999
LIFE and ARBITER.
    Preventive cardiology, 2003,Spring, Volume: 6, Issue:2

    Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Atorvastatin; Carotid Artery Diseases; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Hypertrophy, Left Ventricular; Losartan; Pravastatin; Pyrroles; Treatment Outcome

2003
The combination of nebivolol plus pravastatin is associated with a more beneficial metabolic profile compared to that of atenolol plus pravastatin in hypertensive patients with dyslipidemia: a pilot study.
    Journal of cardiovascular pharmacology and therapeutics, 2003, Volume: 8, Issue:2

    Topics: Adrenergic beta-Antagonists; Anticholesteremic Agents; Atenolol; Benzopyrans; Drug Therapy, Combination; Ethanolamines; Female; Humans; Hyperlipidemias; Hypertension; Male; Nebivolol; Pilot Projects; Pravastatin

2003

Other Studies

15 other study(ies) available for atenolol and pravastatin

ArticleYear
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
    Current drug discovery technologies, 2004, Volume: 1, Issue:4

    Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration

2004
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
    Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7

    Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding

2008
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
    Journal of medicinal chemistry, 2008, Oct-09, Volume: 51, Issue:19

    Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship

2008
Physicochemical determinants of human renal clearance.
    Journal of medicinal chemistry, 2009, Aug-13, Volume: 52, Issue:15

    Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight

2009
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
    European journal of medicinal chemistry, 2009, Volume: 44, Issue:11

    Topics: Blood Proteins; Chemistry, Physical; Computer Simulation; Humans; Membranes, Artificial; Models, Biological; Pharmaceutical Preparations; Protein Binding; Tissue Distribution

2009
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
    European journal of medicinal chemistry, 2010, Volume: 45, Issue:3

    Topics: Administration, Oral; Humans; Models, Chemical; Neural Networks, Computer; Permeability; Quantitative Structure-Activity Relationship; Technology, Pharmaceutical

2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
    Journal of medicinal chemistry, 2010, Feb-11, Volume: 53, Issue:3

    Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations

2010
Prediction of drug intestinal absorption by new linear and non-linear QSPR.
    European journal of medicinal chemistry, 2011, Volume: 46, Issue:1

    Topics: Humans; Intestinal Absorption; Linear Models; Molecular Conformation; Nonlinear Dynamics; Permeability; Pharmaceutical Preparations; Probability; Quantitative Structure-Activity Relationship; Thermodynamics

2011
QSAR-based permeability model for drug-like compounds.
    Bioorganic & medicinal chemistry, 2011, Apr-15, Volume: 19, Issue:8

    Topics: Caco-2 Cells; Cell Membrane Permeability; Drug Discovery; Humans; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship

2011
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
    Journal of medicinal chemistry, 2012, May-24, Volume: 55, Issue:10

    Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection

2012
Clinical trials and clinical practice--bridging the gaps in type 2 diabetes. An evidence-based approach to risk factor modification in type 2 diabetes.
    Australian and New Zealand journal of medicine, 2000, Volume: 30, Issue:4

    Topics: Anticholesteremic Agents; Antihypertensive Agents; Atenolol; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Evidence-Based Medicine; Humans; Hypertension; Hypoglycemic Agents; Metformin; Myocardial Ischemia; Practice Guidelines as Topic; Pravastatin; Risk Factors

2000
[Primary prevention of stroke. What helps--what does not help? The guidelines of the German Society of Neurology briefly summarized].
    MMW Fortschritte der Medizin, 2003, Volume: 145 Suppl 1

    Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Aged; Alcohol Drinking; Anticholesteremic Agents; Anticoagulants; Antihypertensive Agents; Arrhythmias, Cardiac; Aspirin; Atenolol; Atrial Fibrillation; Carotid Artery, Internal; Carotid Stenosis; Chlorthalidone; Clinical Trials as Topic; Diabetes Complications; Diuretics; Doxazosin; Female; Fibrinolytic Agents; Hormone Replacement Therapy; Humans; Hyperlipidemias; Hypertension; Hypolipidemic Agents; Life Style; Losartan; Male; Neurology; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Pravastatin; Primary Prevention; Risk Factors; Simvastatin; Smoking; Societies, Medical; Stroke

2003
LC and LC-MS methods for the investigation of polypills for the treatment of cardiovascular diseases. Part 1. Separation of active components and classification of their interaction/degradation products.
    Journal of pharmaceutical and biomedical analysis, 2008, Jul-15, Volume: 47, Issue:3

    Topics: Aspirin; Atenolol; Atorvastatin; Cardiovascular Agents; Chromatography, High Pressure Liquid; Drug Combinations; Drug Interactions; Drug Stability; Heptanoic Acids; Hydrochlorothiazide; Lisinopril; Pravastatin; Pyrroles; Simvastatin; Spectrometry, Mass, Electrospray Ionization

2008
3D printing of five-in-one dose combination polypill with defined immediate and sustained release profiles.
    Journal of controlled release : official journal of the Controlled Release Society, 2015, Nov-10, Volume: 217

    Topics: Aspirin; Atenolol; Delayed-Action Preparations; Drug Combinations; Drug Liberation; Excipients; Hydrochlorothiazide; Powder Diffraction; Pravastatin; Printing, Three-Dimensional; Ramipril; Solubility; Spectroscopy, Fourier Transform Infrared; Tablets; X-Ray Diffraction

2015